vs
Side-by-side financial comparison of BANNER CORP (BANR) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $169.3M, roughly 1.8× BANNER CORP). BANNER CORP runs the higher net margin — 32.3% vs 16.4%, a 15.9% gap on every dollar of revenue. On growth, BANNER CORP posted the faster year-over-year revenue change (5.7% vs -1.5%). Over the past eight quarters, BANNER CORP's revenue compounded faster (13.0% CAGR vs 1.3%).
Banner Bank is a Washington-chartered commercial bank headquartered in Walla Walla, Washington, with roots that date back to 1890. The bank provides services in commercial real estate, construction, residential, agricultural and consumer loans. It also provides community banking services through its branches and loan offices located in Washington, Oregon, Idaho and California.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
BANR vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $169.3M | $311.4M |
| Net Profit | $54.7M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 32.3% | 16.4% |
| Revenue YoY | 5.7% | -1.5% |
| Net Profit YoY | 21.2% | 126.0% |
| EPS (diluted) | $1.60 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $169.3M | $311.4M | ||
| Q4 25 | $152.4M | $295.9M | ||
| Q3 25 | $150.0M | — | ||
| Q2 25 | $144.4M | $317.0M | ||
| Q1 25 | $141.1M | $316.2M | ||
| Q4 24 | $140.5M | $297.0M | ||
| Q3 24 | $135.7M | $289.5M | ||
| Q2 24 | $132.5M | $306.1M |
| Q1 26 | $54.7M | $51.0M | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $53.5M | — | ||
| Q2 25 | $45.5M | $-17.7M | ||
| Q1 25 | $45.1M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $45.2M | $33.6M | ||
| Q2 24 | $39.8M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 10.0% | 18.4% | ||
| Q3 25 | 13.8% | — | ||
| Q2 25 | 12.3% | -7.5% | ||
| Q1 25 | 13.5% | 12.2% | ||
| Q4 24 | 14.3% | 16.0% | ||
| Q3 24 | 13.3% | 13.8% | ||
| Q2 24 | 13.0% | 15.0% |
| Q1 26 | 32.3% | 16.4% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 31.5% | -5.6% | ||
| Q1 25 | 32.0% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 33.3% | 11.6% | ||
| Q2 24 | 30.0% | 13.3% |
| Q1 26 | $1.60 | $0.32 | ||
| Q4 25 | $1.49 | $0.24 | ||
| Q3 25 | $1.54 | — | ||
| Q2 25 | $1.31 | $-0.11 | ||
| Q1 25 | $1.30 | $0.14 | ||
| Q4 24 | $1.34 | $0.22 | ||
| Q3 24 | $1.30 | $0.21 | ||
| Q2 24 | $1.15 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.0B | $2.1B |
| Total Assets | $16.3B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $422.6M | $172.9M | ||
| Q3 25 | $672.9M | — | ||
| Q2 25 | $483.3M | $162.2M | ||
| Q1 25 | $441.9M | $140.7M | ||
| Q4 24 | $501.9M | $177.5M | ||
| Q3 24 | $478.8M | $187.5M | ||
| Q2 24 | $247.5M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $2.0B | $2.1B | ||
| Q4 25 | $1.9B | $2.0B | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | $1.9B | ||
| Q1 25 | $1.8B | $2.0B | ||
| Q4 24 | $1.8B | $2.1B | ||
| Q3 24 | $1.8B | $2.1B | ||
| Q2 24 | $1.7B | $2.1B |
| Q1 26 | $16.3B | $2.6B | ||
| Q4 25 | $16.4B | $2.5B | ||
| Q3 25 | $16.6B | — | ||
| Q2 25 | $16.4B | $2.6B | ||
| Q1 25 | $16.2B | $2.6B | ||
| Q4 24 | $16.2B | $2.7B | ||
| Q3 24 | $16.2B | $2.7B | ||
| Q2 24 | $15.8B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BANR
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
